These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26646037)

  • 41. Sodium valproate and clozapine induced neutropenia: A case control study using register data.
    Malik S; Lally J; Ajnakina O; Pritchard M; Krivoy A; Gaughran F; Shetty H; Flanagan RJ; MacCabe JH
    Schizophr Res; 2018 May; 195():267-273. PubMed ID: 28882687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.
    Shuman MD; Trigoboff E; Demler TL; Opler LA
    J Psychiatr Pract; 2014 Jan; 20(1):50-8. PubMed ID: 24419309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of clozapine-induced granulocytopenia with lithium (two observations)].
    Papetti F; Darcourt G; Giordana JY; Spreux A; Thauby S; Feral F; Pringuey D
    Encephale; 2004; 30(6):578-82. PubMed ID: 15738861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebroventricular clozapine would be a viable treatment modality for clozapine-dependent schizophrenia patients with neutropenia.
    Alisky JM
    Med Hypotheses; 2012 Oct; 79(4):497-9. PubMed ID: 22818272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reversible neutropenia with olanzapine following clozapine-induced neutropenia.
    Thangadurai P; Jyothi KS; Gopalakrishnan R; Kuruvilla A; Jacob KS
    Am J Psychiatry; 2006 Jul; 163(7):1298. PubMed ID: 16816247
    [No Abstract]   [Full Text] [Related]  

  • 46. Severe clozapine-induced agranulocytosis: successful treatment with G-CSF and rechallenge of clozapine plus D2 potentiation therapy (amisulpride).
    Ruiz-Doblado S; Plasencia-García de Diego B; Perea-Pérez R; Jiménez-Gonzalo F
    Actas Esp Psiquiatr; 2020 Mar; 48(2):89-91. PubMed ID: 32463914
    [No Abstract]   [Full Text] [Related]  

  • 47. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.
    Maher KN; Tan M; Tossell JW; Weisinger B; Gochman P; Miller R; Greenstein D; Overman GP; Rapoport JL; Gogtay N
    J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):110-6. PubMed ID: 23510445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia.
    Mathewson KA; Lindenmayer JP
    J Clin Psychopharmacol; 2007 Dec; 27(6):714-5. PubMed ID: 18004146
    [No Abstract]   [Full Text] [Related]  

  • 49. Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents.
    Wu SY; Liu CC; Hsieh MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1089-90. PubMed ID: 18407390
    [No Abstract]   [Full Text] [Related]  

  • 50. Use of lithium in clozapine-induced neutropenia: a case report.
    Suraweera C; Hanwella R; de Silva V
    BMC Res Notes; 2014 Sep; 7():635. PubMed ID: 25214394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hematological adverse events in clozapine-treated children and adolescents.
    Gerbino-Rosen G; Roofeh D; Tompkins DA; Feryo D; Nusser L; Kranzler H; Napolitano B; Frederickson A; Henderson I; Rhinewine J; Kumra S
    J Am Acad Child Adolesc Psychiatry; 2005 Oct; 44(10):1024-31. PubMed ID: 16175107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series.
    Béchard L; Morasse-Bégis M; Corbeil O; Hakim JR; Malenfant E; Brodeur S; Huot-Lavoie M; Essiambre AM; Demers MF; Roy MA
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):391-395. PubMed ID: 35546087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of clozapine-induced granulocytopenia/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia.
    Rajagopal G; Graham JG; Haut FF
    J Intellect Disabil Res; 2007 Jan; 51(Pt 1):82-5. PubMed ID: 17181606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience of maintaining clozapine medication in patients with 'red-alert zone' neutropenia: long-term follow-up results.
    Ahn YM; Jeong SH; Jang HS; Koo YJ; Kang UG; Lee KY; Kim YS
    Int Clin Psychopharmacol; 2004 Mar; 19(2):97-101. PubMed ID: 15076018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases.
    Manu P; Lapitskaya Y; Shaikh A; Nielsen J
    Am J Ther; 2018; 25(2):e218-e223. PubMed ID: 29505490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.
    Smith RL; Haslemo T; Andreassen OA; Eliasson E; Dahl ML; Spigset O; Molden E
    CNS Drugs; 2017 Nov; 31(11):991-997. PubMed ID: 28948574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing outcomes in clozapine rechallenge following neutropenia using human leukocyte antigen typing: A case report.
    Yamaki N; Hishimoto A; Otsuka I; Sasada T; Boku S; Saito T; Yasuda Y; Yamamori H; Ikeda M; Ikeda M; Sora I; Iwata N; Hashimoto R
    Psychiatry Clin Neurosci; 2017 Apr; 71(4):289-290. PubMed ID: 28097743
    [No Abstract]   [Full Text] [Related]  

  • 58. Clozapine, agranulocytosis, and benign ethnic neutropenia.
    Rajagopal S
    Postgrad Med J; 2005 Sep; 81(959):545-6. PubMed ID: 16143678
    [No Abstract]   [Full Text] [Related]  

  • 59. Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use.
    Demers MF; Fortier L; Corbeil O; Breault AS; Roy MA
    Asian J Psychiatr; 2020 Feb; 48():101541. PubMed ID: 30314715
    [No Abstract]   [Full Text] [Related]  

  • 60. Clozapine-associated severe eosinophilia following lithium rebound neutropenia: A case report.
    Kikuchi K; Yasui-Furukori N; Yokoyama S; Hasegawa C; Kokubun A; Katsukura S; Shimizu T; Shimoda K
    Neuropsychopharmacol Rep; 2020 Dec; 40(4):388-391. PubMed ID: 32951324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.